EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Development of tri-cistronic CLDN18.2 CAR-T cells incorporating PD-1/CD28 switch and cyclophilin A for enhanced solid tumor immunotherapy

Heon Ju Lee, Seo Jin Hwang, Eun Hee Jeong, Mi Hee Chang, Bu Yeon Heo, Jaeyul Kwon, Yoona Noh, Jihoon Nah

Journal of Microbiology · 2026

DOI: 10.71150/jm.2510017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Microbiology, 2026. Verfasst von Heon Ju Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: CARBio Therapeutics Co., Ltd., Cheongju 28160, Republic of Korea. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, CD28 Antigens, Receptors, Chimeric Antigen, Claudins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of SMEs and Startups, Chungbuk Regional Innovation System & Education Center, Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR)-T cell therapy holds significant potential for the treatment of solid tumors. However, immune suppression and tumor-specific barriers limit its application. Claudin 18.2 (CLDN18.2), a gastric lineage-specific tight junction protein highly expressed in gastric and pancreatic cancers, is a promising therapeutic target. In this study, we aimed to develop a next-generation tri-cistronic CLDN18.2-directed CAR-T cell platform that integrates a programmed cell death protein 1 (PD-1)/CD28 chimeric switch receptor with cyclophilin A (CypA). This platform sought to counteract PD-1–mediated immunosuppression and enhance T-cell activation and persistence. We generated CLDN18.2 CAR-T cells incorporating costimulatory inducible T-cell costimulator (ICOS) domains using lentiviral vector-based recombinant engineering. We further evaluated their cytokine release, cytotoxic activity, and safety profiles. In vitro, tri-cistronic CAR-T cells exhibited markedly increased interferon γ and tumor necrosis factor α secretion and enhanced cytotoxicity against CLDN18.2-positive gastric cancer cells compared with conventional CAR-T constructs. In vivo, these cells showed superior antitumor efficacy and sustained tumor regression without observable toxicity in xenograft gastric cancer models. Collectively, these findings demonstrate that the integration of PD-1/CD28 signaling and CypA within a tri-cistronic framework significantly reinforces CAR-T cell functionality and durability. This suggests strong clinical potential as a next-generation immunotherapy for solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Programmed Cell Death 1 ReceptorCD28 AntigensReceptors, Chimeric AntigenClaudinsT-LymphocytesImmunotherapy, AdoptiveStomach NeoplasmsNeoplasmsAnimalsHumansMiceCell Line, TumorXenograft Model Antitumor AssaysInterferon-gammaImmunotherapyFemale

Stichwörter der Autor:innen

Claudin18.2 (CLDN18.2) antigenPD-1/CD28 chimeric switch receptorcyclophilin A (CypA)gastric cancerimmune checkpoint modulationtri-cistronic CAR-T cells

Substanzen

Programmed Cell Death 1 ReceptorCD28 AntigensReceptors, Chimeric AntigenClaudinsCLDN18 protein, humanPDCD1 protein, humanInterferon-gamma

Autor:innen und Institutionen

  • CARBio Therapeutics Co., Ltd., Cheongju 28160, Republic of Korea.
  • Translational Immunology Institute, Department of Medical Education, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea.
  • Department of Biological Sciences and Biotechnology, Chungbuk National University, Cheongju 28644, Republic of Korea.
  • Department of Biochemistry, Chungbuk National University, Cheongju 28644, Republic of Korea.

Förderung

  • Ministry of SMEs and Startups
  • Chungbuk Regional Innovation System & Education Center
  • Ministry of Education

Zitieren

APA

Lee, H. J., Hwang, S. J., Jeong, E. H., Chang, M. H., Heo, B. Y., Kwon, J., Noh, Y., & Nah, J. (2026). Development of tri-cistronic CLDN18.2 CAR-T cells incorporating PD-1/CD28 switch and cyclophilin A for enhanced solid tumor immunotherapy. Journal of Microbiology. https://doi.org/10.71150/jm.2510017

Vancouver

Lee HJ, Hwang SJ, Jeong EH, Chang MH, Heo BY, Kwon J, et al. Development of tri-cistronic CLDN18.2 CAR-T cells incorporating PD-1/CD28 switch and cyclophilin A for enhanced solid tumor immunotherapy. Journal of Microbiology. 2026. doi:10.71150/jm.2510017

BibTeX
@article{Lee2026,
  author = {Lee, Heon Ju and Hwang, Seo Jin and Jeong, Eun Hee and Chang, Mi Hee and Heo, Bu Yeon and Kwon, Jaeyul and Noh, Yoona and Nah, Jihoon},
  title = {Development of tri-cistronic CLDN18.2 CAR-T cells incorporating PD-1/CD28 switch and cyclophilin A for enhanced solid tumor immunotherapy},
  journal = {Journal of Microbiology},
  year = {2026},
  doi = {10.71150/jm.2510017}
}
Kostenlos starten →